UBS Group’s European Biotech Acquisition Corp. Warrant EBACW Stock Holding History

UBS Group’s Portfolio EBACW Stock Details EBACW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-300	Closed	-$90	–	11352
2022 Q4	$90	Sell	300 -600	-67%	-$121	﹤0.01%	10413
2022 Q3	$0	Sell	900 -100	-10%	-$11	﹤0.01%	11464
2022 Q2	$0	Sell	1,000 -400	-29%	-$68	﹤0.01%	11448
2022 Q1	$0	Buy	1,400 +1,000	+250%	+$467	﹤0.01%	11324
2021 Q4	$0	Buy	+400	New	+$256	﹤0.01%	11065

UBS Group's EBACW Position: Q1 2023 in Review

UBS Group sold out of European Biotech Acquisition Corp. Warrant (EBACW) in Q1 2023, closing a stake of 300 shares — an estimated $90 sold.

UBS Group first reported a position in EBACW in Q4 2021 and held it in 5 quarters. The position peaked at $90 in Q4 2022. 0 funds tracked by Wall St. Rank hold EBACW as of Q1 2023.

UBS Group reported no remaining European Biotech Acquisition Corp. Warrant position as of Q1 2023 after selling out during the quarter.
UBS Group sold 300 European Biotech Acquisition Corp. Warrant shares in Q1 2023, an estimated $90.
UBS Group first reported a position in European Biotech Acquisition Corp. Warrant in Q4 2021 and held it in 5 quarters.
UBS Group's European Biotech Acquisition Corp. Warrant position peaked at $90 in Q4 2022.
0 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Warrant as of Q1 2023.

Based on UBS Group's 13F filing for Q1 2023, filed 12 May 2023.